Long non-coding RNA PCAT-1 contributes to tumorigenesis by regulating FSCN1 via miR-145-5p in prostate cancer

Xu, Weihua; Chang, Junkai; Du, Xiang; Hou, Jingli

doi:10.1016/j.biopha.2017.09.019

Cited by 74 publications

(63 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We also verified that the posttranscriptional silencing of PCAT-1 by miR-215 or PCAT-1 siRNAs significantly inhibited HCC cell proliferation and, conversely, that the inhibition of endogenous miR-215 upregulated PCAT-1 expression and promoted cell viability [41]. Additionally, the restoration of miR-145-5p attenuated the induction effects of PCAT1 on prostate cancer progression [42]. However, SNPs in lncRNA PCAT-1 are varied and also influence susceptibility to different types of cancer.…”

supporting

confidence: 62%

Association between lncRNA GAS5, MEG3, and PCAT-1 Polymorphisms and Cancer Risk: A Meta-Analysis

Dong¹,

Gao

et al. 2020

Disease Markers

View full text Add to dashboard Cite

Purpose. Long noncoding RNAs (lncRNAs) have been widely studied, and single nucleotide polymorphisms (SNPs) in lncRNAs are considered to be genetic factors that influence cancer susceptibility. The lncRNA GAS5, MEG3, and PCAT-1 polymorphisms are shown to be possibly associated with cancer risk. The aim of this meta-analysis was to systematically evaluate this association. Methods. Studies were selected from PubMed, Web of Science, Embase, Google Scholar, Cochrane Library, the Chinese National Knowledge Infrastructure (CNKI), and the Chinese Biomedical Literature Database (CBM) through inclusion and exclusion criteria. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using the random-effects model or fixed-effects model to assess the association between lncRNA polymorphisms and cancer susceptibility. Metaregression and publication bias analyses were also conducted. All analyses were performed using the Stata 12.0 software. Results. Sixteen articles (covering 13750 cases and 17194 controls) were included in this meta-analysis. A significant association between SNP rs145204276 and gastric cancer risk was observed (del vs. ins: OR = 0:79, 95%CI = 0:72-0:86; del/del vs. ins/ins+del/ins: OR = 0:74, 95%CI = 0:59-0:91; del/ins vs. ins/ins: OR = 0:84, 95%CI = 0:67-1:05). For rs16901904, a decreased cancer risk was observed in three genetic models (C vs. T: OR = 0:79, 95%CI = 0:70-0:90; CC vs. CT+TT: OR = 0:49, 95%CI = 0:37-0:65; CC vs. TT: OR = 0:49, 95%CI = 0:37-0:66). No statistical significance was found in the metaregression analysis. For all of the included SNPs, no publication bias was found in all genotype models. Conclusions. The rs145204276 SNP in lncRNA GAS5 is likely to be associated with gastric cancer risk, whereas the rs16901904 SNP in lncRNA PCAT-1 bears association with a decreased cancer risk.

show abstract

supporting

confidence: 62%

Association between lncRNA GAS5, MEG3, and PCAT-1 Polymorphisms and Cancer Risk: A Meta-Analysis

Dong¹,

Gao

et al. 2020

Disease Markers

View full text Add to dashboard Cite

show abstract

“…Recently, several scholars have indicated that PCAT1 and PCA3 are important genomic biomarkers for PCa. PCAT1 may accelerate PCa cell proliferation, migration, and invasion as well as suppress apoptosis by upregulating FSCN1 via miR-145-5p (Xu et al, 2017). PCAT1 has attracted attention as a potential prognostic marker and therapeutic target in multiple types of human cancer Qiao et al, 2017;Cui et al, 2017).…”

Section: Discussionmentioning

confidence: 99%

Data Mining and Expression Analysis of Differential lncRNA ADAMTS9-AS1 in Prostate Cancer

et al. 2020

View full text Add to dashboard Cite

Long noncoding RNAs (lncRNAs) play important roles in the regulation of gene expression by acting as competing endogenous RNAs (ceRNAs). However, the roles of lncRNAassociated ceRNAs in oncogenesis are not fully understood. The present study aims to determine whether a ceRNA network can serve as a prognostic marker in human prostate cancer (PCa). In order to identify a ceRNA network and the key lncRNAs in PCa, we constructed a differentially expressed lncRNAs (DELs)-differentially expressed miRNAs (DEMis)-differentially expressed mRNAs (DEMs) regulatory network based on the ceRNA theory using data from the Cancer Genome Atlas (TCGA). We found that the DELs-DEMis-DEMs network was composed of 27 DELs nodes, seven DEMis nodes, and three DEMs nodes. The 27 DELs were further analyzed with several public databases to provide meaningful information for understanding the functional roles of lncRNAs in regulatory networks in PCa. We selected ADAMTS9-AS1 to determine its role in PCa and found that ADAMTS9-AS1 significantly influences tumor cell growth and proliferation, suggesting that it plays a tumor suppressive role. In addition, ADAMTS9-AS1 functioned as ceRNA, effectively becoming a sponge for hsa-mir-96 and modulating the expression of PRDM16. These results suggest that ceRNAs could accelerate biomarker discovery and therapeutic strategies for PCa.

show abstract

“…A plenty of lncRNAs attracted the attention of many scientists, proved that several lncRNAs involved in the regulatory mechanism of PCa, including lncRNA PCGEM1, lncRNA SOCS2‐AS1, lncRNA CTBP1‐AS, lncRNA DRAIC and lncRNA PCAT29 . Xu et al found that PCAT‐1 promoted proliferation, migration, invasion and repressed apoptosis of PCa cells. What's more, it's also been reported that up‐regulation of MEG3 in prostate cancer cell lines induces cell apoptosis and G0/G1 phase arrest .…”

Section: Discussionmentioning

confidence: 99%

“…More and more reports proved that long non‐coding RNAs (lncRNAs) impacted cell proliferation, apoptosis and tumour prognosis . Resent reports proved that lots of lncRNA functioned as carcinogens or tumour suppressors in diverse tumours, including PCa . For example lncRNA SNHG1 promoted cell proliferation in prostate cancer .…”

Section: Introductionmentioning

confidence: 99%

LncRNA MEG3 inhibits the progression of prostate cancer by modulating miR‐9‐5p/QKI‐5 axis

Huang

Chen

et al. 2018

J Cellular Molecular Medi

136

102

View full text Add to dashboard Cite

This study was designed to detecting the influences of lncRNA MEG3 in prostate cancer. Aberrant lncRNAs expression profiles of prostate cancer were screened by microarray analysis. The qRT‐PCR and Western blot were employed to investigating the expression levels of lncRNA MEG3, miR‐9‐5p and QKI‐5. The luciferase reporter assay was utilized to testifying the interactions relationship among these molecules. Applying CCK‐8 assay, wound healing assay, transwell assay and flow cytometry in turn, the cell proliferation, migration and invasion abilities as well as apoptosis were measured respectively. LncRNA MEG3 was a down‐regulated lncRNA in prostate cancer tissues and cells and could inhibit the expression of miR‐9‐5p, whereas miR‐9‐5p down‐regulated QKI‐5 expression. Overexpressed MEG3 and QKI‐5 could decrease the abilities of proliferation, migration and invasion in prostate cancer cells effectively and increased the apoptosis rate. On the contrary, miR‐9‐5p mimics presented an opposite tendency in prostate cancer cells. Furthermore, MEG3 inhibited tumour growth and up‐regulated expression of QKI‐5 in vivo. LncRNA MEG3 was a down‐regulated lncRNA in prostate cancer and impacted the abilities of cell proliferation, migration and invasion, and cell apoptosis rate, this regulation relied on regulating miR‐9‐5p and its targeting gene QKI‐5.

show abstract

Long non-coding RNA PCAT-1 contributes to tumorigenesis by regulating FSCN1 via miR-145-5p in prostate cancer

Cited by 74 publications

References 26 publications

Association between lncRNA GAS5, MEG3, and PCAT-1 Polymorphisms and Cancer Risk: A Meta-Analysis

Association between lncRNA GAS5, MEG3, and PCAT-1 Polymorphisms and Cancer Risk: A Meta-Analysis

Data Mining and Expression Analysis of Differential lncRNA ADAMTS9-AS1 in Prostate Cancer

LncRNA MEG3 inhibits the progression of prostate cancer by modulating miR‐9‐5p/QKI‐5 axis

Contact Info

Product

Resources

About